News
The Society of Cannabis Clinicians keeps you up-to-date on cannabis in clinical practice, industry trends, and policy critiques.
Read original content from the SCC below. Mentions of the SCC online and in print can be found in “SCC In the Press”.
Humboldt Humbled by Legalization
Although it’s entitled “How Legalization Changed Humboldt County Marijuana,” Emily Witt’s article in the New Yorker is not about new plant varieties but about new social realities.
You Must Remember This (Re: Mushrooms)
Eating mushrooms may reduce the risk of cognitive impairment, according to a study published in the Journal of Alzheimer’s Disease.
Epidiolex Weighs in at Schedule V
EPIDIOLEX®, a cannabidiol oral solution has been transferred to Schedule V, the lowest restriction classification, by the U.S. Drug Enforcement Administration. But CBD remains on Schedule I, due to its supposed abuse liability.
Russo’s Grand Unified Theory
Dr. Ethan Russo’s research on the Grand Unified Theory (GUT) that discusses how cannabis-based treatment and nutritional approaches can address five conditions that are difficult to treat with conventional medicine.
Meiri Publishes in Nature
In this seminal study, Dr. Dedi Meiri and his team from Israel enhance our knowledge of the content, effect, and variability of cannabinoids across 36 individual cannabis cultivars.
Our Letter to the Editor of JAMA
SCC Board Members oppose several key provisions JAMA wants the state medical boards to adopt.
Beyond-THC Chemovar Evaluation Survey
The Society of Cannabis Clinicians developed a survey in 2011 that asked about patients’ responses to CBD-rich cannabis.
SCC Hears McAllister On Cannabis Cancer Research
Researchers have discovered that CBD (Cannabidiol) is a very potent inhibitor of breast cancer metastasis. Doctors who monitor cannabis use by patients were bursting with questions during a talk by Sean McAllister, PhD, who has been studying the anti-cancer effects of cannabinoids in the laboratory.